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Abstract: 
Aim: To determine the polyp detection rate and per-patient sensitivity for polyps >9 mm of colon 
capsule endoscopy (CCE) compared with colonoscopy as well as the diagnostic accuracy of CCE.  
Method: Individuals who had positive immunochemical faecal occult blood test during screening had 
investigator blinded colon capsule endoscopy and colonoscopy. Participants underwent repeat endoscopy 
if significant lesions detected by colon capsule endoscopy were considered to have been missed by 
colonoscopy.  
Results: There were 253 participants. The polyp detection rate was significantly higher in colon capsule 
endoscopy compared with colonoscopy (P=0.02). The per-patient sensitivity for >9mm polyps for CCE and 
colonoscopy was 87% (95%CI: 83%-91%) and 88% (95% CI: 84-92) respectively. In participants with 
complete colon capsule endoscopy and colonoscopy examinations (N=126), per-patient sensitivity of >9 
mm polyps in colon capsule endoscopy (97%; 95% CI: 94-100) was superior to colonoscopy (89%; 95% CI: 
84-94). A complete capsule endoscopy examination (N=134) could detect patients with intermediate or 
greater risk (according to the European guidelines) with an accuracy, sensitivity, specificity and positivity 
rate of 79%, 93%, 69% and 58% respectively, using a cut-off of at least one polyp >10 mm or more than two 
polyps.  
Conclusion: Colon capsule endoscopy is superior to colonoscopy in polyp detection rate and per-patient 
sensitivity to >9 mm polyps, but only in complete CCE examinations. The rate of incomplete colon capsule 
endoscopy examinations must be improved.  
Keywords: Colon capsule endoscopy, Colonoscopy, Colorectal cancer screening 
NCT02303756 
  
What does this paper add to the literature?: 
With a complete examination, CCE is a highly sensitive method of detecting neoplasia in the colon and is 
more sensitive than colonoscopy.  We believe that, with increasing completion rates, appropriate rapid 
reporting and refined bowel preparation, CCE could have a significant impact on CRC screening.   
Introduction: 
Colorectal cancer (CRC) screening has been implemented in many European countries in order to 
detect early cancers and high-risk adenomas with the primary aim of reducing colorectal cancer mortality. 
Most screening programmes include a two-stage procedure with a primary faecal occult blood test (FOBT) 
followed by optical colonoscopy (OC) for positive tests. The efficacy of the screening is hampered by the 
suboptimal sensitivity and specificity of FOBT [1] and imperfect OC[2] sensitivity and low population 
acceptance rates. This necessitates repeated screening rounds and results in missed lesions, interval 
cancers, unnecessary investigations and a substantial burden on endoscopy and pathology units. The 
development of alternative strategies is desirable to reduce the number of colonoscopies without 
compromising the effect of screening.  
Colon capsule endoscopy (CCE) is a relatively new technique that has been proposed as a filter for 
referral to OC in CRC screening programmes, and was found to reduce the need for colonoscopy by 71% in 
a study of 63 individuals[3]. The second generation CCE has a reported sensitivity and specificity for 
detecting polyps of >9 mm of 87% and 95%, respectively.[4]. Two studies, of 50 and 62 patients, have 
investigated the accuracy of CCE compared with colonoscopy in immunochemical fecal occult blood 
test(IFOBT) positive screening individuals, reporting sensitivities and specificities for polyps >9 mm from 89-
93% and 92-96%, respectively [3, 5]. The present study is currently the largest trial investigating the polyp 
detection rate (PDR) and accuracy of second-generation CCE compared with OC in an immunochemical 
FOBT (IFOBT) positive screening population. 
The primary aim of this study was the PDR of CCE compared with OC. Secondary outcomes were the 
sensitivity of CCE to detect patients with >9 mm polyps compared with OC, and the ability of CCE to detect 
individuals at intermediate risk or greater according to the European guidelines for stratification of 
colorectal cancer screening risk [6]. 
Method: 
This was a prospective comparative study of IFOBT positive screening individuals investigated with 
second generation CCE, compared with a screening colonoscopy performed the next day. When significant 
findings on CCE were suspected to have been missed by OC, participants were offered a repeat endoscopy. 
Trial participants were recruited from the first round of the national CRC screening programme on the 
island of Funen, Denmark. In Denmark, all citizens aged 50-74 years are invited to have a single sample 
IFOBT (OC-Sensor DIANA; Eiken Chemical Co., Japan) with a hemoglobin concentration cut-off level of 20μg 
haemoglobin per gram of faeces (Hb/gF). Invitations to participate in the study were distributed alongside 
the letter informing the person that the IFOBT test was positive and the consequent invitation for OC. 
Exclusion criteria were previous bowel surgery (except appendicectomy), inflammatory bowel disease, 
renal insufficiency, cardiac pacemaker and symptoms of bowel obstruction. Participants were scheduled for 
CCE one day prior to the planned OC. The CCE examination was performed using PillCam Colon II 
(Medtronic, USA) as a home delivered service by trained nurses (Corporate Health, Germany), who 
supported the participants throughout the procedure. Bowel preparation was polyethylene glycol based 
solution (Moviprep, Norgine, Denmark) for cleansing and boosters (Table 1). All OC’s were performed at a 
single centre by trained senior endoscopists who had been approved for screening investigations using Evis 
Exera III 190 colonoscopes and scope guides (Olympus, Japan). The endoscopists were blinded to the 
results of the CCE examination. They reported bowel preparation quality and all neoplastic findings by 
anatomic location, morphology and size. Pathology reports were conducted according to the European 
guidelines for colorectal cancer screening[6]. The CCE report was provided in three working days by trained 
staff (Corporate Health, Hamburg, Germany) using Rapid Reader Software (Medtronic, USA). It included 
information on capsule excretion (complete transit whilst recording), transit time, bowel preparation 
quality, and anatomic location of findings, morphology, and size. For the anatomic location of lesions, the 
colon was divided into three sections (right, transverse and left colon including rectum). Bowel preparation 
was evaluated in OC and CCE on a five point scale (not acceptable, poor, intermediate, good and excellent). 
Preparations rated as excellent, good, intermediate or poor were defined as clinically acceptable in CCE and 
OC. The CCE and OC reports were evaluated by one of two senior consultants and the participants were 
informed of the results. If OC was incomplete due to insufficient preparation or inability to reach the 
caecum patients underwent either repeat colonoscopy or CT colonography. If significant lesions were found 
at CT colonography, patients had another colonoscopy under general anaesthesia. Findings from these 
examinations were included in the OC findings. In the case of suspected missed polyps by OC the 
participants were offered a repeat endoscopy and in all cases where a second endoscopy was performed 
the endoscopist was unblinded to the findings of the CCE examination. After completion of all endoscopic 
examinations, participants were risk stratified according to the European guidelines for colorectal cancer 
screening [6].  
Statistical methods 
Sample size was calculated as non-inferiority between CCE and OC estimating a PDR in CCE and OC of 
70%, a power of 80%, alpha of 5% and delta of 10%, rendering a total of 260 individuals acting as their own 
control. All polyps found during any OC, including the repeat endoscopies occasioned by the CCE findings or 
subsequent therapeutic endoscopies for polyp removal, were considered true positive findings. Thus, 
findings made by CCE and OC were compared with all findings after completion of additional endoscopies 
when calculating accuracy of CCE and OC in polyp detection. Polyps reported at CCE were matched to 
polyps found in OC by size only, using a per-patient approach. If a size of +/- 50% of the CCE measure 
overlapped with a size of +/- 50% by endoscopist or pathologist measure, it was considered a potential 
match. Polyps could be size matched regardless of location. Based on the size of the largest polyp found, 
patients were categorized as having >9 mm polyps or not. The largest measured size by CCE, endoscopist or 
pathologist was used. Analyses of PDR and per-patient sensitivity and specificity were done for all 
participants and for the subgroup of participants who had a complete CCE and a complete OC. Analyses of 
CCE accuracy in risk stratification was performed on all participants with a complete CCE. Statistical 
analyses were conducted using STATA 14 (Texas, USA).  Results are expressed as proportions or rates with 
95% confidence interval (95%CI) and compared using the chi-squared test as appropriate.  A p-value <0.05 
was considered significant. 
Ethics 
 All included participants received oral and written information and gave signed informed consent. The 
trial was registered at clinicaltrials.gov (NCT02303756) and approved by the local ethics committee 
(S20140141), and the Danish data protection agency. 
 
Results: 
A total of 1458 consecutive invitations were sent out to IFOBT positive individuals and 380 called the 
project nurse for consideration of inclusion. Seventy-four were excluded and 306 individuals initially 
consented to participate, but 45 withdrew their consent before the examinations were scheduled. Seven 
individuals were excluded before the examinations as they did not adhere to the bowel preparation 
protocol (n=6) or were not able to swallow the video capsule (n=1). One individual was excluded because 
consent was withdrawn subsequent to the CCE examination. A total of 253 participants underwent CCE and 
OC and provided data for analyses (figure 1). Fifty-eight percent were men, and the median age was 64 
years.  
CCE and OC completion rates 
The completion rate of OC examinations (90%; 95% CI: 86-94) was significantly higher (p<0.001) 
compared with CCE (54%; 95% CI: 48-60). A total of 126 participants (50%) had a complete CCE and OC and 
were included in the subgroup analyses of per-patient sensitivity and specificity. The estimation of bowel 
preparation was significantly better (p<0.001) in OC (95% acceptable; 95% CI: 92-98) compared with CCE 
(85% acceptable; 95% CI: 81-89). The rate of capsules excreted while recording (CCE excretion rate) was 
57%, but eight of the 145 excreted had an unacceptable bowel preparation, leaving 137 (54%) suitable for a 
complete diagnostic investigation, and were included in CCE risk stratification accuracy analyses. For 
excreted capsules the transit time was <10 hours for 90% (95% CI: 85-95), and the recording time in the 
incomplete examinations exceeded 12 hours in 83% (95% CI: 76-90).  
Adverse events  
There were no serious adverse events related to the diagnostic procedures of CCE and OC. There were 
no retained or impacted capsules, and no bowel preparation or booster related complications or side 
effects. However, of the 26 therapeutic endoscopies performed with endoscopic mucosal resection there 
were seven complications. Five had rectal bleeding, of whom one required blood transfusion and three 
underwent endoscopy to ensure haemostatic control. Two participants had bowel perforation, one was 
managed conservatively and one had surgery.     
CCE and OC findings 
There was a significantly higher PDR in CCE compared with OC in all patients (74% and 64% 
respectively, p=0.02), and in CCE compared with OC in those undergoing complete investigations (86% and 
65% respectively, p<0.001) as shown in Table 2. Adenoma detection rate (ADR) in OC was 53% (95%CI: 47-
59).  
The total number, size, location and pathology of polyps found by CCE, OC, and repeat endoscopies are 
shown in Table 3. CCE and OC detected a total of 483 and 434 polyps respectively. Polyps were reported as 
larger by CCE compared with OC and CCE reported a higher proportion of polyps in the right colon, while 
OC reported a higher proportion in the transverse colon. In the left colon findings were comparable. Sixty 
percent of all polyps retrieved by OC were adenomas. 13% of polyps removed were lost and not retrieved 
for pathology. Eleven adenocarcinomas were confirmed by OC and histology. In five of these the CCE 
reported suspicious large mass at the correct location and in two patients CCE reported a matching polyp 
that was later found to harbour cancer. In four participants, due to incomplete transit, the capsule did not 
pass the site of cancer while recording. 
Repeat endoscopic findings: 
Fifty-three individuals (21%) underwent repeat endoscopy due to findings on CCE, considered to be 
missed at OC (table 3). As a result, 82 additional polyps were retrieved, contributing to 16% of all polyps 
detected. Twenty-four of these polyps were >9 mm and 11 participants with no detected >9 mm polyps on 
OC had a >9 mm polyp retrieved at repeat endoscopy. Forty-six percent of polyps were found in the right 
colon and 46% of the polyps were adenomas. PDR and ADR at the repeat endoscopies were 85% and 59% 
respectively. The adenomas retrieved at the repeat endoscopies increased the ADR in all participants from 
53% to 57% (P=0.37), and resulted in risk reclassification of 12 individuals with an additional 5 high risk, 3 
intermediate risk and 4 low risk patients who had no findings at OC. 
Sensitivity and specificity: 
The CCE per-patient sensitivity and specificity (Table 4) for polyps >9 mm for all participants were 87% 
(95%CI: 83%-91%) and 92% (95%CI, 89%-95%) respectively compared with 88% (95% CI: 84-92) and 100% 
(95% CI: 100) in OC. In the complete investigations group, the CCE per-patient sensitivity and specificity was 
97% (95%CI: 94-100) and 90% (95%CI, 85%-95%) respectively compared with 89% (95% CI: 84-94) and 100% 
(95% CI: 100) for OC. Comparing only complete examinations, CCE sensitivity was higher than OC, while OC 
had a higher specificity. 
Risk stratification accuracy of CCE: 
Figure 2 demonstrates the CCE accuracy, sensitivity and specificity in detecting individuals at 
intermediate risk or greater and the CCE positivity rate according to a continuum of polyp size thresholds 
determined by the size of the largest reported polyp in complete CCE examinations (N=137). The maximal 
accuracy of 85% was reached with a threshold polyp size of 11 mm, with a sensitivity of 88%, a specificity of 
82% and a positivity rate of 48%.   
Figure 3 demonstrates the CCE accuracy, sensitivity and specificity in detecting individuals at 
intermediate risk or greater and the CCE positivity rate according to a continuum of polyp number 
thresholds determined by the reported number of polyps in complete CCE examinations (N=137). The 
maximal accuracy of 72% was reached with a threshold polyp number of more than two, with a sensitivity 
of 58%, a specificity of 83% and a positivity rate of 34%. 
When the two criteria were combined (at least one polyp ≥ 11 mm or ≥ 3 polyps detected) the accuracy 
of CCE was 79%, with a sensitivity and specificity of 93% and 69% respectively and a positivity rate of 58%. 
Discussion: 
This is the largest trial performed to date investigating the performance of CCE against OC in a 
screening programme of IFOBT positive individuals. It is also the first trial to consistently report PDR for CCE 
and OC as well as ADR for OC as an OC quality measure. This outcome has been shown to correlate with the 
risk of interval cancer [7] and is widely used as a screening quality indicator. Despite a poor CCE completion 
rate in this trial, PDR was significantly higher in CCE compared with OC overall. CCE was also superior in per-
patient sensitivity of polyps >9 mm in complete examinations. Unsurprisingly OC had a perfect sensitivity 
since the method is not prone to false positive findings. In OC the completion rate, ADR, and proportion of 
polyps lost were similar to or better than the national average according to the national CRC screening 
database in Denmark (90% vs. 87%, 53% vs. 50 % and 13% vs. 26% respectively)[8]. This confirms that the 
quality of the colonoscopies performed was good, providing a sound basis for comparison. The low 
excretion rate of CCE in this study is insufficient for routine clinical use and impacts the overall performance 
of CCE, resulting in four adenocarcinomas not observed by CCE due to incomplete examinations. All four 
undetected cancers were situated distally in the colorectum and in a position not investigated by the 
capsule. This suggests that an incomplete CCE examination in an IFOBT positive screening individual would 
have to be supplemented by optical endoscopy. The poor excretion rate is likely to have been due to the 
lack of a potent booster, but the design of this study was constrained by the regulations of the national 
screening programme which stipulates that only Moviprep® may be used as a booster for safety reasons. 
Our study strongly indicates that better booster regimens should be used to make CCE feasible in CRC 
screening; excretion rates of >90% have been reported in several trials using more powerful boosters [9-11] 
demonstrating that high excretion rates are feasible and that attention to the choice of bowel preparation 
and boosters in future trials is important.  
The discrepancy between polyps reported by CCE and OC can be caused by either false positive findings by 
CCE or false negative findings by OC. We believe, the discrepancies are mostly due to false negative findings 
in OC, because a substantial number of additional polyps were found by repeat endoscopy and an 
appreciable miss-rate by OC has been well established by back-to-back colonoscopy [2]. The delay between 
CCE and OC could have resulted in a poorer preparation at OC compared with daily clinical practice, 
resulting in polyps being missed. CCE reported polyps as being larger than OC, but pathology measures 
were also larger than OC measures, suggesting that there might be underestimation of polyp size by OC and 
overestimation by CCE. There were also differences in the proportion of polyps reported according to the 
different colonic segments examined between OC and CCE, but due to the high rate of incomplete CCE 
examinations, numbers are difficult to compare.   
The IFOBT sensitivity for small adenomas has been reported to be 7%[12]resulting in the vast majority of 
potentially low risk individuals being IFOBT negative. This indicates that the primary screening health 
benefit arises from advanced adenoma and cancer detections. The high sensitivity of complete CCE 
examinations in detecting individuals later classified as intermediate risk or greater, is thus an acceptable 
basis for being a filter test in CRC screening. The individuals at risk missed by this approach are likely to be  
outweighed by more effective colonoscopies after CCE because the endoscopists could be guided by the 
CCE findings.      
With the level of complete CCE examinations reported in this paper, CCE is clearly not yet suitable for 
introduction into the screening algorithm. However, we have shown that, in a substantial proportion of 
patients, it is feasible to carry out OC as a next-day procedure after CCE using the same bowel preparation 
and that, with complete examination, CCE is a highly accurate method of detecting neoplasia in the colon. 
Indeed, we have shown that for neoplasia, a complete CCE is likely to be more sensitive than OC.  We 
therefore believe that, with appropriate rapid reporting and refined bowel preparation techniques CCE 
could have a significant impact on CRC screening.  Future research should focus on these areas, on 
classification and recognition of significant disease and on the cost effectiveness of screening strategies 
incorporating CCE. 
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Table 1: Bowel preparation and booster regimen  
Day Preparation 
-2 Morning: 1000 mg oral magnesium-oxide 
2 L of water 
Evening: 1000 mg oral magnesium-oxide 
-1 Clear fluids diet 
Evening: 1 L Moviprep and 2½ L of water 
0 Morning: 1 L Moviprep and 1½ L of water. 
60-90 minutes of fasting 
Capsule ingestion 
 with 20 mg oral domperidon 
Booster 1: ¾ L Moviprep and ½ L Water 
Booster 2: ¼ L Moviprep and ¼ L of water 
 10 mg rectal bisacodyl 
Clear fluids diet 
1 Colonoscopy 
 
 
 
 
Table 2: Polyp detection rate (PDR) by colon capsule endoscopy (CCE) and optical screening colonoscopy 
(OC) and adenoma detection rate (ADR) by OC.   
 All participants (N=253) Complete investigations group 
(N=126) 
 OC CCE P-value OC CCE P-value 
PDR, % (95% CI) 64 (58-70) 74 (69-79) 0.02 65 (57-73) 86 (80-92) <0.001 
ADR, % (95% CI) 53 (47-59) N/A  52 (43-61) N/A  
 
 
 
 
Table 3: Polyps detected in Colon capsule endoscopy (CCE), optical colonoscopy (OC) and repeat endoscopy 
by size, location and pathology. 
 CCE 
(N=253) 
OC 
(N=253) 
Repeat 
endoscopy 
(N = 53) 
Total polyps detected, N 483 434 82 
Size, N (%) 
< 6 mm  
6-9 mm 
> 9 mm 
Unknown 
 
141 (29) 
183 (38) 
159 (33) 
0 (0) 
 
216 (50) 
115 (26) 
93 (21) 
10 (2) 
 
36 (44) 
18 (22) 
24 (30) 
4 (5) 
Location, N (%) 
Right colon 
Transverse colon 
Left colon/Rectum 
Unknown 
 
168 (35) 
32 (7) 
281 (58) 
2 (0) 
 
98 (23) 
51 (12) 
285 (66) 
0 (0) 
 
38 (46) 
13 (16) 
30 (37) 
1 (1) 
Pathology, N (%) 
Non-neoplastic 
Adenoma, LGD‡ 
Adenoma, HGD§ 
Adenocarcinoma 
Unknown 
 
 
 
N/A 
 
 
107 (25) 
255 (59) 
4 (1) 
11 (3) 
57 (13) 
 
30 (37) 
38 (46) 
0 (0) 
0 (0) 
14 (17) 
‡LGD: Low grade dysplasia,§High grade dysplasia.  
Table 4: Per-patient sensitivity and specificity in detection of polyps by colon capsule endoscopy (CCE) and 
optical screening colonoscopy (OC), compared with all findings by all OC’s including repeat endoscopies.    
 All participants 
 (N=253) 
Complete investigations group 
(N=126) 
Sensitivity, % 
(95% CI) 
Specificity, % 
(95% CI) 
Sensitivity, % 
(95% CI) 
Specificity, % 
(95% CI) 
CCE  
polyps >9 mm 
 
87 (83-91) 
 
92 (89-95) 
 
97 (94-100) 
 
 
90 (85-95) 
OC 
polyps >9 mm  
 
 
88 (84-92) 
 
100 (100) 
 
89 (84-94) 
 
100 (100) 
 
*CCE: Colon capsule endoscopy, ^OC#: Sequentially numbered optical screening colonoscopy, ~CT: 
Computed Tomography 
Figure 1: Flowchart  
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